Clinical trials: MAB
Effect Increased, Safety Issues
Bronchoscopic Microwave Intervention Treatment in Advanced Central NSCLC
A randomized, prospective study of the efficacy and safety of the first-line treatment in advanced central non-small cell lung cancer patients by anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy versus anti-PD-1 / PD-L1…
- Trial name
- NCT04360655
- Testing
- bronchoscopic microwave intervention, anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
- Volunteers
- 50 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Psoriasis
Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis
The purpose of this study is to determine whether teplizumab is safe when administered subcutaneously (by needle under the skin) in subjects with psoriasis.
- Trial name
- NCT00954915
- Testing
- teplizumab
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- MacroGenics
Healthy
Dose Escalation Study of PF-06741086 In Healthy Subjects
This Phase 1 first-in-human single ascending dose study will be a randomized, double-blind, placebo-controlled investigation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06741086.
- Trial name
- NCT02531815
- Testing
- PF-06741086
- Where
- Belgium
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypercholesterolemia
A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects
JS002 is a recombinant humanized Anti- PCSK9 monoclonal antibody; This is a phase Ia, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single…
- Trial name
- NCT04197817
- Testing
- JS002
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Prostate Cancer
A Study of Olaratumab (IMC-3G3) in Prostate Cancer
This is a study evaluating the safety and efficacy of the monoclonal antibody olaratumab plus mitoxantrone plus prednisone compared to mitoxantrone plus prednisone in metastatic castration-refractory prostate cancer following…
- Trial name
- NCT01204710
- Testing
- Olaratumab, Mitoxantrone, Prednisone
- Where
- 40 sites in Belgium, Czechia and 5 more
- Volunteers
- 123 people
- Sponsor
- Eli Lilly and Company
Pancreatic Cancer
Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00042939
- Testing
- cetuximab, docetaxel, irinotecan hydrochloride
- Volunteers
- 94 people
- Sponsor
- Eastern Cooperative Oncology Group
Paroxysmal Nocturnal Hemoglobinuria
Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria
The purpose of this study was to determine whether LFG316 can induce a hematological response, as measured by reduction in hemolytic activity, in patients with paroxysmal nocturnal hemoglobinuria (PNH).
- Trial name
- NCT02534909
- Testing
- LFG316, LNP023
- Where
- 7 sites in Czechia, Japan and 1 more
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Polyneuropathies
Rituximab to Treat Neuropathy With Anti-MAG Antibodies
This study will test the safety and effectiveness of the drug Rituximab in treating a nerve disease called MGUS (also known as neuropathy with anti-MAG antibodies).
- Trial name
- NCT00050245
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Advanced Cancers
HAI Abraxane With Gemcitabine and Bevacizumab
The goal of this clinical research study is to find the highest tolerable dose of Abraxane® (nab-paclitaxel) when given directly into the liver, in combination with Gemzar® (gemcitabine) and Avastin® (bevacizumab) when given by…
- Trial name
- NCT01057264
- Testing
- HAI Abraxane, Gemcitabine, Bevacizumab
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer
Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment
An experimental treatment with OvaRex® MAb-B43.13 (oregovomab), called immunotherapy is being tested in ovarian cancer patients. Immunotherapy causes the body's defenses to react against cancer cells.
- Trial name
- NCT00086632
- Testing
- oregovomab
- Volunteers
- 40 people
- Sponsor
- Unither Pharmaceuticals
Inflammatory Bowel Disease, Ulcerative Colitis
Safety of Anti-tumor Necrosis Factor (TNF) Monoclonal Antibodies in Inflammatory Bowel Disease
Anti-TNF (tumor necrosis factor) monoclonal antibodies have revolutionized management of Inflammatory bowel disease. Their common features include high efficacy but also immunogenicity and increased infection risk.
- Conditions
- Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease, Indeterminate Colitis
- Trial name
- SATIMOS (NCT02066272)
- Where
- 2 sites in Poland
- Volunteers
- 400 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Colonic Polyps, Polyposis Coli
Non-Invasive Prediction of Colorectal Neoplasia
Hypothesis:The Adnab-9 antigen is a predictive biomarker in individuals at risk of developing colorectal neoplasia. Study aim is to evaluate the potential of the Adnab-9 monoclonal antibody (MAb) as a marker of cancer risk in a…
- Conditions
- Colonic Polyps, Polyposis Coli, Colorectal Cancer
- Trial name
- NIPCON (NCT01815463)
- Where
- United States
- Volunteers
- 2,282 people
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma
Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma
Neoadjuvant therapy of cisplatin-based chemotherapy has been proved to improve prognosis of muscle invasive UTUC patients in several studies.
- Trial name
- NCT04672330
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 16 people
- Sponsor
- RenJi Hospital
Severe Prednisone Dependent Eosinophilic Asthma
Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies
In severe prednisone-dependent eosinophilic asthma, Benralizumab would suppress airway eosinophilia that is not suppressed by either Mepolizumab or Reslizumab and this would be associated with greater asthma control
- Trial name
- NCT03470311
- Testing
- Benralizumab
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- McMaster University
Bacillus Anthracis (Anthrax)
Monoclonal Antibody for Treatment of Inhalation Anthrax
The purpose of this study is to evaluate the safety and pharmacokinetics (how long a drug stays in the bloodstream and how high the levels of the drug are at different times) of ETI-204 following intravenous (IV-into a vein)…
- Trial name
- NCT00138411
- Testing
- Ciprofloxacin 500 mg, ETI-204 (Anthim)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy, Plaque Psoriasis
A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.
This is a first-in-human, randomized, double- blind, placebo-controlled, dose escalation study to investigate how different doses of CAN10 are tolerated, taken up by the body and how long CAN10 stays in the body.
- Trial name
- NCT06143371
- Testing
- CAN10
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Pseudomonas Aeruginosa Pneumonia
Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia
Prospective, double-blind, randomized assessment of the efficacy, safety and pharmacokinetic of Aerucin® as adjunct treatment (in addition to standard of care antibiotics) for pneumonia caused by P. aeruginosa.
- Trial name
- NCT03027609
- Testing
- AR-105
- Where
- 111 sites in United States, Australia and 15 more
- Volunteers
- 158 people
- Sponsor
- Aridis Pharmaceuticals, Inc.
Leukemia, Lymphoma
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia
RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00004084
- Testing
- indium In 111 LL2 IgG, yttrium Y 90 epratuzumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Allergic Rhinitis
An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated Hayfever
This study will investigate whether a single dose QAX576 (an interleukin-13 monoclonal antibody) gives protection against a model of hayfever
- Trial name
- NCT00584584
- Testing
- QAX576
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 36 people
- Sponsor
- Novartis
Thyroid Eye Disease
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
- Trial name
- NCT05517421
- Testing
- Batoclimab
- Where
- 93 sites in United States, Canada and 7 more
- Volunteers
- 114 people
- Sponsor
- Immunovant Sciences GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.